clindamycin inhibits bacterial protein synthesis at the ribosomal (50s sub-unit) level.

absorption:

clindamycin hydrochloride is rapidly absorbed from the canine gastrointestinal tract following oral administration.  effective clindamycin antibacterial serum levels are reached within 30 minutes following administration of the therapeutic dose.

 serum values:

therapeutic serum levels of clindamycin can be maintained by oral administration of 5.5 mg/kg bodyweight every 12 hours or 11 mg/kg bodyweight every 24 hours; peak serum concentrations are on average reached 75 minutes after oral administration.  the biological plasma half-life of clindamycin in the dog is approximately 5 hours.  no accumulation of bioactivity has been observed in dogs after several oral administrations.

metabolism and excretion:

extensive research of the metabolism and excretion pattern of clindamycin shows that the parent molecule as well as bioactive and bio-inactive metabolites is excreted via the urine and faeces.  nearly all bioactivity in the serum following oral administration is due to the parent molecule (clindamycin).

indications:

clindamycin uncoated tablet are indicated for use in dogs as follows:

for the treatment of infected wounds and abscesses, and infected mouth cavity and dental infections, caused by or associated with staphylococcus spp, streptococcus spp (except streptococcus faecalis), bacteroides spp, fusobacterium necrophorum, and clostridium perfringens. to help provide antimicrobial cover during dental procedures.

for the treatment of superficial pyoderma associated with staphylococcus intermedius.

for the treatment of osteomyelitis, caused by staphylococcus aureus.

before clindamycin therapy is initiated, the involved pathogens should be identified and sensitivity to clindamycin established.

clindamycin inhibits bacterial protein synthesis at the ribosomal (50s sub-unit) level.

absorption:

clindamycin hydrochloride is rapidly absorbed from the canine gastrointestinal tract following oral administration.  effective clindamycin antibacterial serum levels are reached within 30 minutes following administration of the therapeutic dose.

 serum values:

therapeutic serum levels of clindamycin can be maintained by oral administration of 5.5 mg/kg bodyweight every 12 hours or 11 mg/kg bodyweight every 24 hours; peak serum concentrations are on average reached 75 minutes after oral administration.  the biological plasma half-life of clindamycin in the dog is approximately 5 hours.  no accumulation of bioactivity has been observed in dogs after several oral administrations.

metabolism and excretion:

extensive research of the metabolism and excretion pattern of clindamycin shows that the parent molecule as well as bioactive and bio-inactive metabolites is excreted via the urine and faeces.  nearly all bioactivity in the serum following oral administration is due to the parent molecule (clindamycin).

indications:

clindamycin uncoated tablet are indicated for use in dogs as follows:

for the treatment of infected wounds and abscesses, and infected mouth cavity and dental infections, caused by or associated with staphylococcus spp, streptococcus spp (except streptococcus faecalis), bacteroides spp, fusobacterium necrophorum, and clostridium perfringens. to help provide antimicrobial cover during dental procedures.

for the treatment of superficial pyoderma associated with staphylococcus intermedius.

for the treatment of osteomyelitis, caused by staphylococcus aureus.

before clindamycin therapy is initiated, the involved pathogens should be identified and sensitivity to clindamycin established.